OPKO Health (NASDAQ:OPK) Receives “Buy” Rating from HC Wainwright

OPKO Health (NASDAQ:OPK)‘s stock had its “buy” rating reiterated by HC Wainwright in a research report issued to clients and investors on Wednesday,Benzinga reports. They currently have a $3.00 price target on the biotechnology company’s stock. HC Wainwright’s target price would suggest a potential upside of 74.42% from the stock’s previous close.

Other equities analysts have also issued research reports about the company. Barrington Research reissued an “outperform” rating and set a $2.25 price objective on shares of OPKO Health in a research note on Wednesday. StockNews.com upgraded OPKO Health from a “sell” rating to a “hold” rating in a report on Monday, March 3rd.

OPKO Health Trading Down 3.4 %

Shares of OPK opened at $1.72 on Wednesday. The firm’s fifty day moving average is $1.61 and its two-hundred day moving average is $1.57. The stock has a market cap of $1.16 billion, a PE ratio of -9.05 and a beta of 1.70. The company has a quick ratio of 2.69, a current ratio of 2.97 and a debt-to-equity ratio of 0.30. OPKO Health has a 52-week low of $0.86 and a 52-week high of $2.04.

OPKO Health (NASDAQ:OPK) last posted its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.09. The firm had revenue of $183.60 million for the quarter, compared to analyst estimates of $155.42 million. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. Research analysts forecast that OPKO Health will post -0.25 earnings per share for the current fiscal year.

Insider Activity at OPKO Health

In related news, CEO Phillip Md Et Al Frost bought 150,000 shares of the stock in a transaction on Friday, January 17th. The stock was bought at an average price of $1.47 per share, with a total value of $220,500.00. Following the completion of the purchase, the chief executive officer now directly owns 213,186,477 shares in the company, valued at $313,384,121.19. This represents a 0.07 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Over the last three months, insiders have acquired 764,971 shares of company stock worth $1,145,692. Insiders own 47.26% of the company’s stock.

Hedge Funds Weigh In On OPKO Health

Several large investors have recently made changes to their positions in the stock. FMR LLC raised its position in OPKO Health by 103.6% in the third quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 11,089 shares during the period. Orion Portfolio Solutions LLC acquired a new stake in shares of OPKO Health in the third quarter valued at $45,000. Cibc World Markets Corp acquired a new stake in shares of OPKO Health in the fourth quarter valued at $45,000. Zacks Investment Management purchased a new stake in shares of OPKO Health in the 4th quarter valued at $49,000. Finally, Ieq Capital LLC acquired a new position in OPKO Health during the 4th quarter worth about $52,000. 64.63% of the stock is currently owned by institutional investors and hedge funds.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.